Royalty Pharma Quarterly Cash Flow Statement
NASDAQ: RPRXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Royalty Pharma free cash flow
In the quarter ended Jun 30, 2026, Royalty Pharma generated $728.5 million of operating cash flow. That left free cash flow of $728.5 million, a free-cash-flow margin of 108.1% of revenue. Free cash flow was up 100.1% from the prior year's $364.0 million.
Royalty Pharma returned $44.6 million to shareholders through share repurchases, equal to 6% of free cash flow.
Summary generated from market data by MetaCap's automated system. Methodology
Royalty Pharma cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 81.49M | 468.26M | 355.91M | 444.21M | 92.64M | 434.43M | 334.35M | 806.36M | 194.38M | -4.27M | 717.59M | 122.08M |
| Net Income growth (YoY) | -12.04% | +7.79% | +6.45% | -44.91% | -52.34% | — | -53.41% | +560.53% | -44.67% | -100.84% | — | -44.61% |
| Depreciation & Amortization | 1.29M | 1.17M | 1.20M | 1.28M | 1.38M | 0 | 0 | 0 | — | — | — | — |
| Stock-Based Compensation | 107.07M | 121.99M | 125.77M | 72.84M | 90.77M | 515.00K | 525.00K | 526.00K | 681.00K | 612.00K | 617.00K | 581.00K |
| Change in Working Capital | 7.21M | -6.09M | -28.53M | 10.91M | -6.72M | 10.09M | -5.87M | 7.20M | -6.00K | -3.61M | 4.59M | 3.79M |
| Operating Cash Flow | 728.46M | 718.23M | 827.15M | 702.62M | 363.98M | 596.08M | 742.52M | 703.61M | 658.21M | 664.64M | 772.63M | 573.52M |
| Investing Cash Flow | -229.72M | -477.87M | -847.80M | -958.31M | -311.98M | 503.92M | -505.59M | -1.19B | -893.18M | -86.65M | -1.00B | -450.66M |
| Share Repurchases | -44.64M | -50.10M | -80.54M | -146.49M | -291.57M | -708.78M | -52.61M | -97.05M | -80.00M | 0 | -30.20M | -140.12M |
| Financing Cash Flow | -273.15M | -272.67M | -299.60M | 562.74M | -507.81M | -941.30M | -257.96M | -325.50M | 1.16B | -212.00M | -231.89M | -1.36B |
| Net Change in Cash | 225.59M | -32.30M | -320.25M | 307.04M | -455.81M | 158.69M | -21.03M | -814.59M | 921.64M | 365.99M | -459.44M | -1.24B |
| Free Cash Flow | 728.46M | 718.23M | 827.15M | 702.62M | 363.98M | 596.08M | 742.52M | 703.61M | 658.21M | 664.64M | 772.63M | 573.52M |
This table shows 12 quarterly periods of Royalty Pharma's cash flow statement, from Q2 2026 back to Q3 2023, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow RPRX's reporting calendar. What is a cash flow statement?